Management of submucous uterine fibroid with buserelin, gemeprost and hysteroscopic resection.
A 19-year-old virgin presented with severe menorrhagia and a haemoglobin level of 76 g/L as a problem of management. A 5 cm diameter submucous fibroid was identified at hysteroscopy and biopsied but was unable to be removed. The luteinising hormone releasing hormone agonist, buserelin, was used in an attempt to produce symptomatic relief. One week after commencing buserelin therapy, severe menorrhagia occurred and the patient was admitted to hospital with a haemoglobin concentration of 24 g/L. Buserelin treatment was continued and no further menstruation occurred over the following year. As the patient was now well, hysteroscopic submucous fibroid resection was contemplated. Due to cervical rigidity in this teenager, a 1 mg gemeprost pessary was inserted into the posterior vaginal fornix three hours before surgery. This allowed an operative hysteroscope to be inserted into the uterus and a fibroid resection to be performed. Menstrual blood loss has been normal for six months after hysteroscopy. A combined medical and surgical approach may avoid hysterectomy in such problem patients.
Lawrence
A S
AS
Monash University Department of Obstetrics and Gynaecology, Clayton, Vic.
Healy
D L
DL
Hill
D
D
Paterson
P J
PJ
D000328:Adult; D000527:Alprostadil / Q000008:administration & dosage / Q000031:analogs & derivatives*; D002064:Buserelin / Q000627:therapeutic use*; D002584:Cervix Uteri / Q000187:drug effects; D004106:Dilatation; D005260:Female; D006801:Humans; D015907:Hysteroscopy / Q000379:methods*; D007889:Leiomyoma / Q000150:complications / Q000188:drug therapy / Q000601:surgery*; D008595:Menorrhagia / Q000188:drug therapy / Q000209:etiology; D010570:Pessaries; D014594:Uterine Neoplasms / Q000150:complications / Q000188:drug therapy / Q000601:surgery*
C021182:gemeprost; D000527:Alprostadil; D002064:Buserelin